This trial is evaluating whether Pegilodecakin will improve 2 primary outcomes and 3 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of approximatley 4 months.
This trial requires 350 total participants across 24 different treatment groups
This trial involves 24 different treatments. Pegilodecakin is the primary treatment being studied. Participants will be divided into 24 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Pegilodecakin is similar biochemically to pefloxacin and both are active against gram negative microbes such as Pseudomonas aeruginosa. Their bactericidal action appears to be mediated, at least in part, by a reversible inhibition of cell wall synthesis." - Anonymous Online Contributor
"The cause of carcinoma, non-small-cell lung is not understood. Exposure to asbestos, tobacco, and other toxic agents in the workplace may increase the risk of developing cancer." - Anonymous Online Contributor
"Signs of metastasis of carcinoma, non-small-cell lung, in blood include high levels of lymphocytes, low serum albumin, low levels of lymphocytes with increased serum, and high levels of immunization." - Anonymous Online Contributor
"Approximately 116,000 people will be diagnosed with carcinoma, non-small-cell lung a year in the United States in 2018. This makes up 4.8% of all new cancer diagnoses in the United States." - Anonymous Online Contributor
"It is very difficult to attain a cure for NSCLC. Many patients survive a long time, irrespective of the stage at the time of initial detection. However, once found to have recurrent disease, patients seem to be able to cure themselves once the disease is treated for a second time. Patients with a very low number of disease recurs and a complete surgical resection of a small metastatic lesion may have a good cure, particularly if they show good response to chemotherapy at the initiation of treatment." - Anonymous Online Contributor
"The first-line treatment for localized carcinoma, non-small-cell lung varies significantly among Chinese clinicians, depending largely on the degree of urgency for cure. A combination of chemotherapy, radiation therapy, and surgery, together with a few palliative measures such as topical and systemic analgesia, are recommended by most Chinese clinicians for most patients with carcinoma, non-small-cell lung." - Anonymous Online Contributor
"The prevalence of current and previous smoking is extremely high among patients with NSCLC. The prognosis and survival of patients is worse then what is expected from patients without smoking history (NSCLC). The reason of this association remains elusive and we need further investigations, including a possible epigenetic component." - Anonymous Online Contributor
"The risk factors for lung cancer include tobacco smoking, air pollution, passive smoking, occupational exposure to coal dust, as well as genetics. The risk of developing lung cancer is lower than the incidence." - Anonymous Online Contributor
"In a recent study, findings of recent studies suggest that certain subtypes of non-small-cell lung carcinoma may be responsive to novel treatments of immune checkpoint inhibitors. An update on the available evidence is included in the review." - Anonymous Online Contributor
"For lung carcinoma, we demonstrated a significant survival difference after adjusting for differences in stage. There was no survival difference based on stage among the group with metastasis. Data from a recent study demonstrate a relationship between survival and the time to metastasis. Therefore, we suggest that the concept of occult metastasis in lung carcinoma should be reconsidered in the light of these findings." - Anonymous Online Contributor
"The cancer registry data obtained by the Lung Cancer Information Exchange (LCIe) Program (http://www.federico.bnl.gov/bnl/lctu/lb/lctu/lbcic.htm) are the largest database of cancer survival rates in the world. These data indicate that the survival rate for lung cancer is approximately 17.5% for all NSCLC, 33 to 37% for stage IIIb/IV, and 32% for stages IB/IIA. The difference is less than 30% in overall survival, with a similar proportion at each stage of disease. In this registry, NSCLC survival does appear to depend on gender." - Anonymous Online Contributor
"[Men have a higher chance of developing carcinoma, non-small-cell lung than women; and, women with carcinoma, non-small-cell lung have a higher chance of developing heart disease than men]" - Anonymous Online Contributor